Allogene Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 at 04:14 pm EDT
Allogene Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported net loss was USD 78.19 million compared to USD 66.2 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.52 a year ago. Diluted loss per share from continuing operations was USD 0.57 compared to USD 0.52 a year ago.
For the nine months, net loss was USD 182.14 million compared to USD 181.65 million a year ago. Basic loss per share from continuing operations was USD 1.35 compared to USD 1.55 a year ago. Diluted loss per share from continuing operations was USD 1.35 compared to USD 1.55 a year ago.